• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Introduction to 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid (CAS No. 1006452-51-2)

1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1006452-51-2, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrazole family, a class of molecules known for their diverse biological activities and structural versatility. The presence of a cyclopentyl substituent at the 1-position and a carboxylic acid group at the 4-position introduces unique chemical properties that make it a valuable scaffold for drug discovery and development.

The structure of 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid features a six-membered aromatic ring system consisting of two nitrogen atoms and four carbon atoms, with the cyclopentyl group attached to one of the nitrogen atoms. The carboxylic acid functionality at the 4-position provides a site for further chemical modification, enabling the synthesis of derivatives with enhanced pharmacological properties. This structural motif has been extensively explored in the design of novel therapeutic agents due to its ability to interact with biological targets in multiple ways.

In recent years, 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid has been studied for its potential applications in various therapeutic areas. One of the most promising areas of research is its role as an intermediate in the synthesis of antimicrobial agents. Pyrazole derivatives have shown efficacy against a wide range of bacterial and fungal pathogens, and the incorporation of a cyclopentyl group can enhance binding affinity and metabolic stability. Preliminary studies have indicated that compounds derived from 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid exhibit promising activity against multidrug-resistant strains, making them a subject of intense investigation.

Additionally, this compound has been investigated for its anti-inflammatory properties. The pyrazole core is known to modulate inflammatory pathways by interacting with enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). The cyclopentyl group may further enhance these interactions by improving solubility and bioavailability. Researchers have synthesized several analogs of 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid and evaluated their ability to inhibit pro-inflammatory cytokine production. Some derivatives have demonstrated significant potency in preclinical models, suggesting their potential as lead compounds for novel anti-inflammatory therapies.

The pharmacokinetic profile of 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid is another area of interest. The cyclopentyl group contributes to favorable pharmacokinetic properties such as improved oral bioavailability and reduced clearance rates. These characteristics are crucial for developing drugs that require multiple daily dosing or have short half-lives. Computational modeling studies have been conducted to predict the metabolic pathways and potential drug-drug interactions associated with this compound, providing valuable insights for optimizing its therapeutic potential.

In the realm of neurological disorders, pyrazole derivatives have shown promise as potential treatments for conditions such as Alzheimer's disease, Parkinson's disease, and epilepsy. The ability of 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid to cross the blood-brain barrier makes it an attractive candidate for developing central nervous system (CNS) drugs. Recent studies have focused on its interaction with neurotransmitter receptors and ion channels, which could lead to novel therapeutic strategies for managing neurological symptoms.

The synthetic pathways for producing 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid are also an important consideration in pharmaceutical research. Efficient synthetic routes not only reduce production costs but also improve scalability for industrial applications. Researchers have developed multi-step synthetic strategies that utilize readily available starting materials and transition metal catalysis to achieve high yields and purity. These advancements in synthetic methodology are crucial for translating laboratory discoveries into viable drug candidates.

One notable aspect of 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid is its versatility as a drug scaffold. By modifying different positions on the pyrazole ring or introducing additional functional groups, researchers can generate libraries of compounds with tailored biological activities. This approach is particularly useful in high-throughput screening campaigns aimed at identifying novel lead compounds for various diseases. The combination of computational chemistry tools with experimental validation has accelerated the discovery process, leading to several promising candidates entering clinical trials.

The regulatory landscape surrounding new drug development also plays a critical role in assessing the commercial viability of compounds like 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid. Regulatory agencies require comprehensive data on safety, efficacy, and quality before approving new drugs for market use. Companies investing in this compound must navigate stringent regulatory requirements, ensuring that all aspects of drug development adhere to international standards. This includes preclinical testing, clinical trials, and post-marketing surveillance.

In conclusion, 1-Cyclopentyl-1H-Pyrazole-4-Carboxylic acid (CAS No. 1006452-51-2) represents a significant advancement in pharmaceutical chemistry with broad applications across multiple therapeutic areas. Its unique structural features, combined with promising biological activities, make it a valuable asset in drug discovery efforts. As research continues to uncover new applications and optimize synthetic methodologies, this compound is poised to play an increasingly important role in developing next-generation therapeutics.

• 950858-65-8(1-Tert-butyl-1H-pyrazole-4-carboxylic acid)
• 849612-71-1(1-Propyl-1H-pyrazole-4-carboxylic acid)
• 1103427-25-3(1-(Cyclopropylmethyl)-1H-pyrazole-4-carboxylic acid)
• 1177299-30-7(1-cyclohexyl-1H-pyrazole-4-carboxylic acid)
• 957312-98-0(1-CYCLOHEXYL-1H-PYRAZOLE-4-CARBALDEHYDE)
• 1340372-11-3(1-(oxan-4-yl)-1H-pyrazole-4-carboxylic acid)
• 1170169-27-3(1-(butan-2-yl)-1H-pyrazole-4-carbaldehyde)
• 1622883-44-6(1-Cyclopropyl-1H-pyrazole-4-carboxylic acid)
• 436096-96-7(1-(propan-2-yl)-1H-pyrazole-4-carboxylic acid)
• 1170364-22-3(1-Cyclopentyl-1H-pyrazole-4-carbaldehyde)